8 May 2003

CE Mark for new needle-free drug delivery system

The Medical House PLC (“TMH”), the medical equipment and devices company, announces that its new needle-free drug delivery system, based on its own proprietary technology, has been awarded the CE Mark.

Specifically, this is a further milestone event under the development agreement with BioPartners GmbH, and will now enable BioPartners to conduct trials for the use of the new device for the delivery of human growth hormone.

Commenting, Ian Townsend, Chief Executive of The Medical House PLC, said:

“This is a further step in our strategy to be a provider of drug delivery solutions to major pharmaceutical businesses.”

Notes to Editors

The Medical House PLC (“TMH”) is quoted on AIM and specialises in the design, manufacture and distribution of medical devices and equipment. Its operations include: Eurocut, a company specialising in the design, development and manufacture of instruments for use in orthopaedic surgery; Creative Medical Design, a leading designer of medical devices and manufacturer of prototypes; and Medical House Products which undertakes the development and subsequent sale of medical devices.

BioPartners is headquartered in Zug, Switzerland (www.biopartners.com). It is a global biopharmaceuticals company and a leader in the emerging field of multi-source biopharmaceuticals. BioPartners’ mission is to develop patentable and innovative formulations of “first generation” biopharmaceuticals as well as source advanced delivery systems that may improve patient compliance to its product portfolio. BioPartners is developing a comprehensive range of biopharmaceutical products that may offer life-saving therapeutic benefits across many therapeutic areas, including oncology, virology, haematology, endocrinology and neurology.

CONTACTS:

Ian Townsend (Chief Executive Medical House PLC) 0114 261 9011
John Bick (Holborn) 020 7929 5599